Dual-targeted antibody mosunetuzumab elicits durable responses in poor-prognosis non-Hodgkin Lymphoma patients

Bookmark and Share
Published: 7 Dec 2019
Views: 375
Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA

Prof Stephen Schuster presents data from a study looking at the dual targeted antibody mosunetuzumab during a press conference at the ASH 2019 meeting.

The study evaluated the response and durability of remissions in poor-prognosis non-Hodgkin Lymphoma patients.

Watch ecancer's interview with Prof Schuster here

Read more about the study here